Merck KGaA Stocks Suffer After Missing Earnings Estimates

Shares of Merck KGaA have dropped significantly after the company reported second-quarter earnings that missed analyst estimates by about 30% and revealed tighter profit margins.

Investors are also concerned about a cautious fiscal outlook, rising worries about generic rivals to its key multiple sclerosis drug Mavenclad, and multibillion-dollar charges tied to its Bio-Techne acquisition.

Analysts note that the sell-off appears driven by the gap between Merck's valuation and its underlying profitability rather than broader sector weakness.